Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.
|Title||Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.|
|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Leuchter, AF, Cook IA, Hunter A, Korb A|
|Journal||Clinical EEG and neuroscience : official journal of the EEG and Clinical Neuroscience Society (ENCS)|
|Date Published||2009 Apr|
|Keywords||Antidepressive Agents, Brain, Depressive Disorder, Major, Electroencephalography, Electrophysiological Phenomena, Evoked Potentials, Auditory, Humans, Tomography|
Approximately 50% of patients with Major Depressive Disorder (MDD) respond to the first antidepressant medication prescribed, and fewer than one-third experience remission of symptoms. The most significant challenge in the management of MDD, therefore, is selection of the antidepressant medication that is most likely to lead to response or to remission for an individual patient. There is a growing body of evidence that certain clinical neurophysiologic techniques may be useful for selecting the medication that is most likely benefit each patient. Use of low resolution electromagnetic tomography (LORETA), loudness dependent auditory evoked potentials (LDAEP), and resting state quantitative electroencephalography (QEEG) in the clinical setting is increasingly supported by studies indicating that these techniques may help identify particular medications that are most likely to lead to response or remission. The current state of evidence supporting the use of each technique is reviewed.
|Alternate Journal||Clin EEG Neurosci|